Development of AECOPD Identification Tool (DETECT Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-28

Study Completion Date

2021-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an observational, multi-center and cross sectional study,to develop an identification tool on purpose of differentiating COPD exacerbation from patients with respiratory symptoms in community hospitals of China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population

NCT06724848

COPD

RECRUITING

Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03170999

Airway Obstruction

COMPLETED

Exploring Clinical Predictors of COPD Exacerbation in a Community Cohort

NCT05762861

COPD Exacerbation

UNKNOWN NA

Respiratory Pathogens of Patients With Asthma and COPD Exacerbations

NCT02866357

COPD

COMPLETED

Realize the Current Situation of COPD Patients in China

NCT03131362

Chronic Obstructive Pulmonary Disease COPD

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational, multi-center and cross-sectional study to develop an AECOPD identification tool. Estimated totally 7 tertiary hospitals with experts in respiratory area will be involved as the study sites. These study sites will cover the regions of China (Eastern, Southern, Northern, Central, Western and Northeastern region), to be representative for the patient features all over the country. The patients will be enrolled in a "consecutive" way, which is, the investigators will recruit the patients who are eligible and consented to participate in this study without personal tendency.

For the enrolled patients, a face to face visit between investigator and patient will be arranged. The evaluation for the symptoms and signs will be performed and the relevant data will be collected on the visit. In addition, other relevant tests (e.g. oxygen saturation, blood test, CAT, etc) and data (demographic, medical history, etc) will be collected on this visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Exacerbations of COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Disease 1

Moderate to severe COPD Patients(n=90)

No interventions assigned to this group

Disease type 2-1)

Patients with Mild/moderate AECOPD (n=60)

No interventions assigned to this group

Disease type 2-2)

Patients with Severe AECOPD( n=60)

No interventions assigned to this group

Disease type 3

Non-COPD Patients with high risk factors (n=90)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-≥ 40 years old of age.

* Able to adequately understand written and verbal
* A signed and dated written informed consent must be obtained prior to the visits
* Patients see doctors due to suffering respiratory disease below:

Disease type 1 - diagnosed moderate and severe stable COPD

* Patients with a diagnosis of COPD and documented record with predicted ratio of FEV1 to forced vital capacity (FVC) \< 0.70 before the study visit
* COPD with moderate to severe airflow obstruction (FEV1\<0.8 predicted)

Disease type 2 - AECOPD

* Patients with a diagnosis of COPD and documented record with predicted ratio of FEV1 to forced vital capacity (FVC) \< 0.70 before the study visit
* Patients consult the clinic or the emergency department because of acute worsening with an AECOPD (diagnosed by more than 2 clinical experts and refer to diagnosis criteria of Appendix 2)

Disease type 3

-Non-COPD patients with chronic respiratory symptoms such as cough, sputum and wheeze, dyspnea etc. (≥2 high risk factors )

Exclusion Criteria

* Patients with severe cardiovascular disease, including uncontrolled hypertension with drug treatment, unstable angina, myocardial infarction within the last 6 months, NYHA class II congestive heart failure, severe arrhythmia, pericardial effusion, etc.
* Patients with lung cancer, esophageal cancer or mediastinal tumors;
* Patients who participated in any drug clinical trials within 4 weeks before enrollment;
* Patients with severe infection, indicated for intravenous antibiotics, antifungal or antiviral therapy;
* Patients suffering from mental illness and poor compliance;
* Patients inappropriate for inclusion decided by investigator.

Eligible Sex

ALL

Accepts Healthy Volunteers

No